STOCK TITAN

Integrated BioPharma (INBP) DEF 14A Filings

INBP OTC

Here are the DEF 14A proxy statements from Integrated BioPharma Inc (INBP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBP filings page.

Rhea-AI Summary

Integrated BioPharma, Inc. (INBP) will hold its 2026 annual meeting on November 30, 2026. Stockholders will vote on three Class II director nominees—William H. Milmoe, Christina Kay and Robert Canarick—for terms through the 2029 meeting; ratification of the 2025 Equity Incentive Plan, subject to stockholder approval; and ratification of CBIZ CPAs P.C. as auditor for the fiscal year ending June 30, 2027. The plan authorizes awards covering up to 7,500,000 common shares; its available pool also includes shares remaining or made available through forfeitures under the Prior Plans.

There were 31,059,610 common shares outstanding and entitled to vote on October 15, 2026. The beneficial-ownership table lists Damon DeSantis at 41.4% and directors and executive officers as a group at 67.6%. For fiscal 2026, total compensation was $350,732 for each Co-CEO, Christina Kay and Riva Sheppard, and $360,744 for CFO Dina L. Masi; aggregate bonuses to three named executives were $42,220. The 2025 Plan had 6,773,500 shares remaining for future issuance as of June 30, 2026.